Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: Victrelis

2014: The Year That Changed The Landscape of HCV Therapy

Posted on November 8, 2014 by Harald — No Comments ↓

It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick Continue reading 2014: The Year That Changed The Landscape of HCV Therapy→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email

Like this:

Like Loading...
Posted in The News, The Viewpoint | Tagged approval, Bartenschlager, boceprevir, cirrhosis, DAA, FDA, HAART, Harvoni, HCV, HIV, Incivek, ledipasvir, LLOD, LLOQ, NS3B/4A, NS5a, NS5B, OI, Olysio, Peg-interferon, polymerase, protease, replicon, ribavirin, simeprevir, sofosbuvir, Sovaldi, SVR, telaprevir, Victrelis, viral load, VL | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • Sulopenem uUTI – Does It Suffice?
  • PUBLICATION OVERACHIEVERS
  • BLUJEPA / Gepotidacin APPROVED FOR UNCOMPLICATED UTI – 1
  • Gepotidacin ABSSSI – How to Fail Adaptively
  • A Critical Review of WHO’s List of Antibacterials in Clinical Development
  • Some Thoughts about the New Coronavirus Syndrome and its Transmission
  • Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB
  • The Weak Correlation Between Antibiotic Action and Mortality
  • FDA Needs Radical Reform
  • The Letermovir Top-Line Results are Out – Or Are They?

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Allphase Pharma Consulting aminoglycoside antibiotic blog Avelox Bayer Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA FDA Guidance fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline Orbactiv oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2025 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d